Versican promotes tumor progression, metastasis and predicts poor prognosis in renal carcinoma
- Yozo Mitsui(corresponding author),
- Hiroaki Shiina,
- Taku Kato,
- Shigekatsu Maekawa,
- Yutaka Hashimoto,
- Marisa Shiina
- Shimane University,
- University of California at San Francisco,
- VA Medical Center,
- The University of Osaka,
- Toho University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>The proteoglycan versican (VCAN) promotes tumor progression and enhances metastasis in several cancers; however, its role in clear cell renal cell carcinoma (ccRCC) remains unknown. Recent evidence suggests that VCAN is an important target of chromosomal 5q gain, one of the most prevalent genetic abnormalities in ccRCC. Thus, we investigated whether VCAN expression is associated with the pathogenesis of ccRCC. VCAN expression was analyzed using three RCC and normal kidney cell lines as well as a clinical cohort of 84 matched ccRCC and normal renal tissues. Functional analyses on growth and progression properties were performed using VCAN-depleted ccRCC cells. Microarray expression profiling was employed to investigate the target genes and biologic pathways involved in VCAN-mediated ccRCC carcinogenesis. ccRCC had elevated VCAN expression in comparison with normal kidney in both cell lines and clinical specimens. The elevated expression of VCAN was significantly correlated with metastasis (P < 0.001) and worse 5-year overall survival after radical nephrectomy (P - 0.014). In vitro, VCAN knockdown significantly decreased cell proliferation and increased apoptosis in Caki-2 and 786-O cells, and this was associated with alteration of several TNF signaling-related genes such as TNFa, BID, and BAK. Furthermore, VCAN depletion markedly decreased cell migration and invasion which correlated with reduction of MMP7 and CXCR4. These results demonstrate that VCAN promotes ccRCC tumorigenesis and metastasis and thus is an attractive target for novel diagnostic, prognostic, and therapeutic strategies.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 884-895 (12 pages)Journal (Volume, Issue Number)
Molecular Cancer Research (Volume 15, Issue 7)Publication milestones
- Published - 07/2017
Publication status
Published - 07/2017
ISSN
1541-7786Publication IDs
- Scopus: 85021810372
- PubMed: 28242813
Publication metrics
Metrics
SciVal
FWCI
1.87
SciVal
Author count
20
SciVal
citations
29
SciVal
Paper percentile
93
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.05
Fractional count
19
Fractional count
0.95
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
50
Citation count
73
Mentions
1
Funding Details
This study was supported by Department of Veterans Affairs Merit Review and National Cancer Institute (#R01CA199694) grants.
FundersFunding number
NCI
R01CA199694
VA
-